Press Release - Company Data

Celsion Receives European Orphan Drug Designation for ThermoDox(R) to Treat Primary Liver Cancer
Posted 2011-03-02 11:26NASDAQ_CLSN
, a leading oncology drug development company, today announced that the European Commission (EC) has granted orphan drug designation for the Company's lead compound, ThermoDox(R), a proprietary heat-a

Celsion Announces ThermoDox(R) Preclinical Data Publication and Presentations at Upcoming Scientific Conferences
Posted 2011-03-01 11:33NASDAQ_CLSN
announced today the publication of data highlighting the preclinical efficacy for ThermoDox(R) with High Intensity Focused Ultrasound (HIFU) as well as the presentation of related research abstracts a

Celsion to Present at Cowen and Company 31st Annual Health Care Conference
Posted 2011-03-01 11:32NASDAQ_CLSN
, a leading oncology drug development company, today announced that Michael H.

Celsion Corporation Announces Completion of $5.1 Million Registered Direct Offering
Posted 2011-01-21 15:56NASDAQ_CLSN
,a leading oncology drug development company dedicated to the development and commercialization of innovative oncology drugs, today announced that it has completed its registered direct offering of 5,

Celsion Reports Third Quarter 2010 Financial Results and Provides Business Update
Posted 2011-01-06 02:53NASDAQ_CLSN
, a biotechnology drug development company, today announced financial results for the third quarter and nine months ended September 30, 2010 and addressed the progress of its clinical trials of The

Celsion Receives COMP Recommendation for Orphan Drug Designation in Europe for ThermoDox(R) to Treat Primary Liver Cancer
Posted 2010-11-11 13:31NASDAQ_CAST
, a leading oncology drug development company, today announced that the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) has issued a positive opinion on the appli

Celsion Announces Date and Time Change for Third Quarter 2010 Financial Results Conference Call to Monday, November 15, 2010
Posted 2010-11-10 16:58NASDAQ_CLSN
, a late stage biotechnology drug development company that is leveraging its heat sensitive liposomal platform to encapsulate and deliver high concentrations of proven chemotherapeutics, today announc

Celsion to Hold Third Quarter 2010 Financial Results Conference Call on Thursday, November 11, 2010
Posted 2010-11-08 15:46NASDAQ_CLSN
, a late stage biotechnology drug development company that is leveraging its heat sensitive liposomal platform to encapsulate and deliver high concentrations of proven chemotherapeutics, today announc

Celsion Awarded Therapeutic Discovery Project Grant From US Government Under the Patient Protection and Affordable Care Program
Posted 2010-11-02 14:28NASDAQ_CLSN
today announced that the company has been awarded a $244,000 grant under the Qualifying Therapeutic Discovery Project (QTDP) program under The Patient Protection and Affordable Care Act of 2010 (PPAC

Celsion Announces ThermoDox's Prominence in Abstracts Presented at the 2nd International MR-Guided Ultrasound Symposium
Posted 2010-10-19 09:07NASDAQ_CLSN
announced today that two abstracts on the ThermoDox(R) High Intensity Focused Ultrasound (HIFU) development program have been delivered via oral presentation at the MR-guided Focused Ultrasound 2010 2